Fish oil for dry eyes? Why the studies don't give a simple yes

If you’ve had gritty, burning eyes for months, a bottle promising omega-3 support can look like an easy next step. The catch: in one of the biggest dry-eye trials, people taking fish oil felt better over the year - and so did people taking the comparison oil. The DREAM trial found no significant extra symptom benefit from omega-3. That doesn’t mean nobody could benefit. It does mean a supplement label can’t tell you whether you will.

The trial that complicates the sales pitch

#

DREAM enrolled 535 adults with moderate-to-severe dry eye and compared EPA and DHA (the marine omega-3 fats commonly found in fish oil) against refined olive oil for a year. Participants could continue other dry-eye care. Their average symptom scores improved in both groups: 13.9 points in the omega-3 group and 12.5 in the comparison group, with no statistically significant difference after adjustment. Measures of eye-surface health didn’t show a significant advantage either. DREAM study

So why did both groups improve? The trial doesn’t settle that. Ongoing care, the natural ups and downs of symptoms, the experience of being in a study, or the comparison oil itself could play a part. The important test was whether the omega-3 group did better than the other group, not whether its own scores moved. It didn’t, by a dependable margin in this study. DREAM study

And dry eye isn’t one single problem. Tears can be insufficient or evaporate too quickly; medications and other conditions can contribute. An eye exam can help identify what’s going on before another capsule gets added to the routine. National Eye Institute dry-eye guide

Then why do some reviews sound positive?

#

The answer depends partly on which trials are combined and what they’re being compared against. Cochrane’s 2019 review found little or no difference in symptoms when long-chain omega-3 was compared with placebo or no treatment; the certainty for that comparison was low. It also found a possible symptom benefit when omega-3 was added to usual care in two small trials totaling 70 people. But an add-on comparison against usual care alone doesn’t answer quite the same question as a blinded comparison with a control oil. That smaller signal is worth studying, not a reason to shelve prescribed drops.

A 2023 review of 19 randomized trials reported a pooled improvement in dry-eye symptoms. Trouble is, the symptom results varied enormously between studies (the review reported I² of 96.1%). Pooling can find a signal without showing which patient, formulation or setting produced it. More recently, a 2026 review of 27 trials also found a pooled signal, but benefits weren’t consistent across dry-eye causes and omega-3 forms. Some screen-use and contact-lens subgroups looked more promising; the meibomian-gland-dysfunction subgroup did not show a significant benefit. Those subgroup findings aren’t a prescription for people who wear contacts.

There’s a test of a more specific product, too. In a 2024 randomized trial of 132 people with meibomian-gland-dysfunction (MGD) dry eye, a re-esterified omega-3 formulation wasn’t significantly better for symptoms at 12 weeks than grape-seed oil. Both groups used preservative-free eye drops. Grape-seed oil may not be an inert comparison, and this was a shorter, smaller trial than DREAM. Still, it doesn’t support the easy claim that a different formulation has solved the problem.

These reviews also reuse some of the same underlying trials - their participant totals aren’t separate piles of evidence. And a tear-production measurement isn’t the same thing as feeling less burning or grit. Cochrane reported a small change in one tear test but didn’t judge it clinically meaningful. If you’re deciding whether to spend money or change care, the symptom outcome matters. Cochrane review

What about food instead of capsules?

#

It’s reasonable to think about omega-3-rich foods as part of a balanced diet. Fish and seafood provide EPA and DHA; walnuts, chia and flax provide mostly ALA, which the body converts to EPA and DHA only to a limited extent. But this is general nutrition advice, not proof that eating fish treats dry eye or works better than a capsule for this condition. NIH Office of Dietary Supplements and NCCIH’s omega-3 overview make the food and supplement distinctions; the dry-eye trials don’t provide a direct food-versus-pill answer.

A proposed anti-inflammatory mechanism sounds plausible (and it’s a reason to run trials). It can’t substitute for a person noticing less discomfort. Nor should prevention data be folded into treatment claims: a large trial of people without dry eye at baseline found omega-3 didn’t reduce new dry-eye diagnoses. That’s a different question from treating persistent symptoms.

The safety conversation is part of the decision

#

Fish oil isn’t automatically harmless because it’s sold without a prescription. Bad taste, heartburn, nausea and diarrhea are among the reported annoyances. Check the label if it’s cod-liver oil, too - vitamins A and D can add up. Products differ in their EPA and DHA content, and a plant-based ALA product isn’t interchangeable with the marine EPA/DHA used in the major trials. NCCIH; NIH Office of Dietary Supplements

If you take warfarin or another anticoagulant, bring the specific product to your prescriber before starting it or changing how you use it. There are potential concerns about INR at high fish-oil intakes, though most trials haven’t found a clinically important anticoagulation effect; don’t stop a medicine on your own. And if you’ve had atrial fibrillation or cardiovascular disease, ask about high-dose omega-3 specifically. Large trials in people at cardiovascular risk reported a small increase in atrial fibrillation with high-dose products - not an established risk estimate for an ordinary serving of fish. NIH Office of Dietary Supplements

Pregnant or breastfeeding? Don’t treat these dry-eye trials as a green light for high-dose self-treatment. Ask an obstetric and eye-care clinician about a supplement and suitable low-mercury fish choices. A fish allergy, chronic illness, planned procedure or other prescriptions also make a product-specific conversation sensible. NCCIH; NIH Office of Dietary Supplements

Take the question to the eye exam

#

Rather than asking which fish oil is best, ask what might be driving your symptoms: too few tears, rapid evaporation or MGD, a medication, or something else? Ask which established steps fit the cause. Artificial tears may help mild dry eye, while more serious cases can need clinician-directed treatment. Supplements shouldn’t delay an exam or replace prescribed eye care. National Eye Institute

If you still want to discuss omega-3, bring the bottle or a photo of its label - EPA/DHA content, added vitamins and your medication list are more useful than a front-of-pack promise. Ask how you’d track a real change in symptoms while keeping other care steady. There isn’t a well-established dry-eye supplement dose in this evidence, so copying a study regimen isn’t a do-it-yourself plan. DREAM study; Cochrane review

Persistent redness, light sensitivity or blurry vision deserve an eye assessment, not another round of self-diagnosis. Marked pain or a sudden vision change calls for prompt medical assessment. National Eye Institute

Bottom line: the large placebo-controlled trial and Cochrane’s placebo comparison don’t show a dependable symptom benefit from routine omega-3 supplementation. Other pooled analyses leave questions open, especially about whether particular patients respond. For now, the useful next purchase probably isn’t a bottle. It’s clarity about why your eyes hurt - and a care plan that doesn’t depend on a supplement proving itself later.